跳到正文
原文
Medical Xpress·· 16 天前精选AI 评分65

一种全新的G蛋白偶联受体失活方法

A much-needed new way to inactivate GPCRs, the most common drug targets

AI 导读

哈佛医学院和达纳-法伯癌症研究所的研究团队开发了一种新方法,通过将难以成药的G蛋白偶联受体内化并降解,显著降低了这些受体的活性。该方法在多种细胞模型和动物模型中有效,为药物研发提供了新的途径。

推荐理由

新方法通过将难以成药的G蛋白偶联受体内化并降解,为药物研发提供了新的途径。

正文
A much-needed new way to inactivate GPCRs, the most common drug targets
A new method can block hard-to-drug members of the family of cell-surface receptors known as GPCRs by bringing them inside the cell and destroying them. Here, a significant portion of a GPCR known as CCR6 on the surface of human cells (shown in green) has been pulled inside and begun to degrade four hours after treatment (white, right) compared to the start (left). Credit: Rhee K., Shue L., et al., Nature, Oct. 2026

About one-third of all drugs approved by the U.S. Food and Drug Administration target G protein-coupled receptors (GPCRs), a family of more than 800 cell-surface receptors that regulate a wide range of vital functions, including blood pressure, heart rate and immunity.

These drugs block GPCR function, usually by binding to and preventing their interaction with molecules that would normally bind to and activate them. But this method has limitations.

For example, current drugs don't work well for GPCRs surrounded by high concentrations of the molecules that activate them. The drugs also have no effect on a minority of GPCRs that are always active, producing signals even without an activating molecule. This has left the therapeutic potential of many members of the GPCR family untapped.

Seeking a solution to these shortcomings, four labs at Harvard Medical School and Dana-Farber Cancer Institute combined their expertise to control GPCR signaling in a whole new way. Rather than blocking the receptors' activity, their strategy removes selected GPCRs completely.

Reported in Nature, this approach could be a game-changer for pharmaceuticals and offer a novel way to study this vast receptor family.

"GPCR degradation opens exciting new avenues for developing therapies for patients," said study co-senior author Xin Zhou, HMS assistant professor of biological chemistry and molecular pharmacology at Dana-Farber.

The ties that bind

To rid cell surfaces of certain GPCRs, the researchers relied on a molecular engineering principle called induced proximity—a research focus of the Zhou Lab.

Induced proximity involves so-called bispecific molecules that connect two molecules.

"By being physically tethered together, one biomolecule's function can influence the other's," explained Zhou. "There is a big unmet need in developing induced proximity approaches to target the GPCR family."

The lab is particularly interested in a molecule known as the transferrin receptor 1, or TfR1. Responsible for pulling the iron-carrying protein transferrin into cells, TfR1 continually shuttles back and forth between the cell surface and interior—collectively bringing hundreds of molecules into a single cell per second—and is found on many different cell types in the body.

If they could molecularly link TfR1 to specific GPCRs, Zhou reasoned, it could drag the GPCRs into cells. The right bridging molecule could then route the GPCRs to cellular garbage disposals known as lysosomes that degrade them.

Better than existing blockers

To engineer a bispecific molecule capable of this feat, Zhou's lab teamed up with co-senior author Andrew Kruse, professor of biological chemistry and molecular pharmacology in the Blavatnik Institute at HMS. His lab studies GPCRs with the help of nanobodies, antibody fragments that bind to these receptors. Kruse and colleagues have amassed a large library of nanobodies.

Co-first authors Kaitlin Rhee and Lawrence Shue, Harvard Kenneth C. Griffin Graduate School of Arts and Sciences Ph.D. students in the Zhou Lab, led the work.

They developed bispecific molecules that connect TfR1 to nanobodies that bind specific GPCRs, using a bridge derived from part of an antibody called immunoglobulin G1. This brings the GPCRs into cells, where they can be degraded. The team called these molecules GPCR-TfR1-targeting chimeras, or GTACs.

As a pragmatic proof of principle, the team targeted GPCRs that have key functions in health and disease and a variety of operating mechanisms.

One was the angiotensin II type 1 receptor (AT1R), the target of a class of drugs known as angiotensin receptor blockers. Taken by nearly 6% of U.S. adults, these drugs treat high blood pressure, heart failure and chronic kidney disease. Despite their popularity, Kruse said, they aren't a perfect solution—many patients still have poor symptom control, even on several of these medications combined.

When the researchers treated cells engineered to overexpress both AT1R and TfR1 with an inactivating anti-AT1R nanobody, they reduced AT1R signaling by about 30%—about the same as angiotensin receptor blockers in the same experimental system.

But when they treated cells with the GTAC, they reduced signaling by up to 90%. It prevented activation of other molecules downstream of AT1R as well.

Drugging the undruggable

The team had similar success with RXFP1, a GPCR that binds the hormone relaxin-2, which promotes remodeling of the cardiovascular and other systems in pregnancy; CCR6, a GPCR that regulates inflammation and has been implicated in autoimmune diseases; and BILF1, a GPCR produced by cells infected with the Epstein-Barr virus, which is associated with many cancers.

Researchers have had challenges targeting each of these GPCRs using traditional pharmaceutical approaches. For instance, targeting AT1Rs with angiotensin receptor blockers causes fetal toxicity, so they can't be used to treat preeclampsia, a condition marked by dangerously high blood pressure in pregnancy.

Conventional antibodies struggle to fully block CCR6 because its natural activating molecules bind tightly to the receptor at two different sites. BILF1 remains constantly active without needing any molecule to switch it on, making it difficult to shut down with conventional drugs.

The team's results suggest that GTACs can effectively target GPCRs like these that are considered "undruggable" by contemporary pharmaceutical standards.

The researchers didn't limit their evaluation to engineered cells. Working with the labs of Karen Adelman, the Edward S. Harkness Professor of Biological Chemistry and Molecular Pharmacology at HMS, and Jun Huh, associate professor of immunology at HMS, they also investigated GTACs in cells that naturally express these GPCRs and in animal models.

For example, treating heart cells with the anti-AT1R GTAC significantly reduced their beats, and treating a mouse model of psoriasis with the anti-CCR6 GTAC significantly reduced symptoms.

The team plans to continue exploring GTACs' promise by targeting other major GPCRs—and potentially developing them into a new class of pharmaceuticals.

"This project was really possible because of the incredible scientific community at Harvard Medical School," Kruse said. "Whether across the Quad or across the river, you can access world-class expertise in virtually any field or technology."

Publication details

Kaitlin Rhee et al., GPCR antagonism via rewiring of receptor trafficking and degradation, Nature (2026). DOI: 10.1038/s41586-026-11088-0

Journal information: Nature

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: A much-needed new way to inactivate GPCRs, the most common drug targets (2026, November 4) retrieved 4 November 2026 from https://medicalxpress.com/news/2026-11-inactivate-gpcrs-common-drug.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com